tbuckley/cabot-search huggingface dataset:
Phantom Pain
Authors: Joseph Fermaglich
Journal: JAMA (1997)

Pain is arguably the most common symptom that causes patients to seek medical attention. Localization of pain and associated signs, including heat, swelling, redness, and loss of function, usually establish the diagnosis and treatment. Alternatively, pain may be referred to contiguous or remote sites. Coronary disease presents with pain in the chest, shoulder, arm, or jaw. Ureteral obstruction is announced by pain in the groin or testicle. What, then, can be said about pain that originates in organs or extremities that have been surgically or traumatically removed and no longer exist? That is the subject of<i>Phantom Pain</i>. Beginning with the premise that phantom pain need not be psychogenic, Sherman and associates search a wilderness of causes. Treading a serpentine path from the periphery of the nervous system to the most superficial layers of the cerebral cortex, they speculate about pathogenetic mechanisms: possibly neuroma formation, neuropathy, neurohumoral or autonomic imbalance
Lack of association between coronary angioplasty laboratory volume and outcomes following hospital discharge Stephen E. Kimmel, William H. Sauer, Colleen Brensinger, John Hirshfeld, Howard L. Haber, A. Russell Localio. University of Pennsylvania School of Medicine, Philadelphia, PA, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA
Journal: Journal of the American College of Cardiology (2001)
LISTING AMERICAN HEALTH RESORTS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection and Surveillance of Colorectal Cancer
Authors: David E. Fleischer
Journal: JAMA (1989)

Colorectal cancer is the second most common cause of cancer in the United States. The overall mortality rate approaches 60%. However, the detection of early lesions results in a mortality rate of 20% or less. Therefore, if improvement in survival is to occur, increased efforts need to be focused not only on primary prevention but also on early detection of malignant lesions and the eradication of potentially malignant lesions. There is no universal consensus as to how this can be accomplished. The purpose of this article is to serve as a guideline, providing a practical basis for improving early detection and management of colorectal cancer and its precursors. (<i>JAMA</i>1989;261:580-585)
Time course of improvement of left ventricular function post revascularization: Repetitively stunnings vs hibernation Jeroen J. Bax, Abdou Elhendy, Don Poldermans, Jan H. Cornel, Paolo M. Fioretti, Cees A. Visser, Frans C. Visser. Leiden University Medical Center, Leiden, The Netherlands, Free University Hospital Amsterdam, Amsterdam, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample
Authors: Sayed Mohammad Ebrahim Sahraeian, Li Tai Fang, Konstantinos Karagiannis, Malcolm Moos, Sean Smith, Luis Santana-Quintero, Chunlin Xiao, Michael Colgan, Huixiao Hong, Marghoob Mohiyuddin, Wenming Xiao
Journal: Genome biology (2022)

Accurate detection of somatic mutations is challenging but critical in understanding cancer formation, progression, and treatment. We recently proposed NeuSomatic, the first deep convolutional neural network-based somatic mutation detection approach, and demonstrated performance advantages on in silico data.
Tuberculous meningitis
Authors: Robert J. Wilkinson, Ursula Rohlwink, Usha Kant Misra, Reinout van Crevel, Nguyen Thi Hoang Mai, Kelly E. Dooley, Maxine Caws, Anthony Figaji, Rada Savic, Regan Solomons, Guy E. Thwaites
Journal: Nature Reviews Neurology (2017)
Dispersion in total cost of care for Medicare fee-for-service (FFS) patients with metastatic pancreatic cancer receiving FDA-approved/NCCN Category 1 regimens at 340B verus non-340B institutions.
Authors: Helen Latimer, Samantha Tomicki, Gabriela Dieguez, Paul Cockrum, George P. Kim
Journal: Journal of Clinical Oncology (2021)

e18843 Background: The Department of Health and Human Services (HHS) designed the 340B drug pricing program to allow institutions that service specialty populations to acquire drugs at lower prices. Objective: To analyze the dispersion in total cost of care (TCOC) for Medicare FFS patients (pts) with metastatic pancreatic cancer (m-PANC) treated at 340B or non-340B institutions, by NCCN Category 1 regimen. Methods: We identified pts with m-PANC using ICD-10 diagnosis codes in the 2016-18 Medicare Parts A/B/D 100% Research Identifiable Files. Study pts had 2+ claims with a pancreatic cancer diagnosis and Medicare FFS coverage for 6 months pre- and 3 months post-metastasis diagnosis. Study pts were treated with NCCN Category 1 regimens: 1L gemcitabine monotherapy (gem-mono), 1L gemcitabine/nab-paclitaxel (gem-nab), 1L FOLFIRINOX (FFX), and 2L liposomal irinotecan-based regimen (nal-IRI). Pts were attributed to 340B or non-340B institutions based on plurality of chemotherapy claims. TCOC reflects insurer-paid services per line of therapy (LOT) for 3 categories: chemotherapy/supportive drugs (chemo/Rx), inpatient care (IP), and other outpatient care (OP). We grouped pts by quartile (qrt) and evaluated drivers of TCOC and mean rates of admissions (admits/pt). Results: We identified 2,697 (340B) and 3,839 (non-340B) pts taking NCCN Category 1 regimens. Gem-mono represented 1% and 4% of all pts in 340B and non-340B institutions, respectively. Gem-nab accounted for 72% of pts in both cohorts. For gem-nab, FFX, and nal-IRI pts, median TCOC was similar in both cohorts, although mean TCOC by qrt was lower at 340B institutions than non-340B institutions, except for gem-nab in the 1 st qrt. The components of TCOC were similar between 340B and non-340B institutions in all qrts. In both cohorts, % IP costs increased between the 1 st and 4 th qrt (340B:15% to 23%, non-340B:14% to 25%). From the 1 st to the 4 th qrt, admits/pt increased in both cohorts. In the 340B cohort, nal-IRI pts had the lowest admits/pt while gem-nab pts had the highest in all qrts. In the non-340B cohort, nal-IRI pts had the lowest admits/pt except for in the 1 st qrt. Conclusions: Median TCOC was lower at 340B institutions than non-340B institutions for all regimens, and the range of TCOC dispersion was also smaller at 340B institutions. Across qrts, chemotherapy accounted for approximately half the TCOC; however, IP costs were proportionally higher in the 4 th qrt. Comparing regimens, despite 2L nal-IRI pts being more heavily pretreated, median costs in each cohort were similar to 1L gem-nab and 1L FFX, while admits/pt were generally lower than 1L gem-nab and 1L FFX across qrts and cohorts.
Early-onset well differentiated pancreatic neuroendocrine tumors: Clinical presentation, pathologic features, and oncological outcomes.
Authors: Alessandra Pulvirenti, Haley Hauser, Tiffany Le, Caitlin A. McIntyre, Diane Lauren Reidy, Alice Chia-chi Wei, Nitya Prabhakar Raj
Journal: Journal of Clinical Oncology (2022)

507 Background: Young onset of several gastrointestinal cancers is associated with more advanced disease and poor oncological outcomes, however, this association has not been fully investigated for well differentiated pancreatic neuroendocrine tumors (PanNET). Our study aimed to evaluate clinical and pathological differences as well as disease outcomes between young-onset PanNET (YO-PanNET) and late-onset PanNET (LO-PanNET). Methods: Patients with localized PanNET who underwent surgery at Memorial Sloan Kettering Cancer Center between 2000 to 2017 were identified. Those with hereditary syndromes, metastatic disease, and postoperative mortality were excluded. YO-PanNET was defined as &lt;50 and LO-PanNET &gt;50 years of age at time of diagnosis. Family history, clinical and pathology characteristics, were recorded. Fisher’s exact test was used to detect difference between the age groups. Kaplan-Meier method was used to investigate age prognostic significance. Results: A total of 366 patients were identified, 84 (23%) with YO-PanNET. Compared with LO-PanNET, YO-PanNET were less likely to have a personal history of another cancer (p&lt;0.001) and a first-line relative with cancer (p&lt;0.015). We did not observe any significant differences between YO-PanNET and LO-PanNET with regards to pathology features such as tumor grade (p=0.7), size (p=0.5), nodal metastases (p=0.8), and stage of disease (p=0.7). With a median follow-up of 68 months (range 0-238), 5-year recurrence-free survival was 76% and 83%, and 10-year RFS was 69% and 78%, respectively, in YO-PanNET and LO-PanNET (p=0.12; see Table) with similar 5- and 10-year overall survival (p=0.31). Conclusions: In this large retrospective surgical series, we found that YO-PanNET is not associated with an increased rate of personal or familial history of cancer. Pathological characteristics and long-term oncological outcomes do not significantly differ between YO-PanNET and LO-PanNET. Current efforts include next-generation sequencing analysis in the resected surgical specimens to evaluate for genomic biomarkers of recurrence.[Table: see text]
Union Médicale du Canada, Montreal
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nature, London
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum for Research Article “Production and transplantation of bioengineered lung into a large-animal model“ by J. E. Nichols, S. La Francesca, J. A. Niles, S. P. Vega, L. B. Argueta, L. Frank, D. C. Christiani, R. B. Pyles, B. E. Himes, R. Zhang, S. Li, J. Sakamoto, J. Rhudy, G. Hendricks, F. Begarani, X. Liu, I. Patrikeev, R. Pal, E. Usheva, G. Vargas, A. Miller, L. Woodson, A. Wacher, M. Grimaldo, D. Weaver, R. Mlcak, J. Cortiella
Journal: Science Translational Medicine (2021)

In the Research Article “Production and transplantation of bioengineered lung into a large-animal model,” the image displayed in fig. S8J of the Supplementary Materials was incorrect and the staining control images displayed in Fig. 4N, fig. S3M, and fig. S3T were shown in duplicate in Fig. 4P, fig. S3O, and fig. S3V, respectively. The legends for the figures were correct as written and remain unchanged. The online PDF and HTML (full text) of main text and the Supplementary Materials have been updated with corrected figure panels for Fig. 4N, fig. S3M, fig. S3V, and fig. S8J.
Knowledge, belief, and moral psychology
Authors: John Mikhail
Journal: Behavioral and Brain Sciences (2021)

Abstract Phillips et al. make a strong case that knowledge representations should play a larger role in cognitive science. Their arguments are reinforced by comparable efforts to place moral knowledge, rather than moral beliefs, at the heart of a naturalistic moral psychology. Conscience, Kant's synthetic a priori, and knowledge attributions in the law all point in a similar direction.
Highlights of the NCCN Oncology Research Program
Authors: Mihaela Cristea, Edward Wang, Daphne Stewart, Mark Wakabayashi, Ernest Han, Thanh Dellinger, Stephen Lee, Lorna Rodriguez, Alexander Jung, Sharon Wilczynski, Michael Tran, ; Gottfried, E Konecny, Joanne Mortimer
Journal: Journal of the National Comprehensive Cancer Network (2021)
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Authors: Stefan S. Bielack, Sigbjorn Smeland, Jeremy Whelan, Neyssa Marina, Jane Hook, Gordana Jovic, Mark D. Krailo, Trude Butterfass-Bahloul, Thomas Kühne, Mikael Eriksson, Lisa A. Teot, Hans Gelderblom, Leo Kager, Kirsten Sundby Hall, Richard Greg Gorlick, R. Lor Randall, Pancras C. W. Hogendoorn, Gabriele Calaminus, Matthew Robert Sydes, Mark L. Bernstein
Journal: Journal of Clinical Oncology (2013)

LBA10504 Background: EURAMOS-1 (NCT00134030) is an international randomized controlled trial investigating treatment optimization in osteosarcoma on the basis of histologic response to preoperative chemotherapy (CT). In patients (pts) with “good response” (GR; &lt;10% viable tumor at surgery) to induction CT, efficacy of maintenance therapy with pegylated interferon α-2b (Ifn) was investigated. Methods: Pts ≤40yrs with resectable localized or primary metastatic high-grade extremity or axial osteosarcoma were eligible for registration at diagnosis. Eligibility for randomization included: [a] receipt of two cycles pre-op methotrexate, doxorubicin, cisplatin (MAP); [b] complete macroscopic resection of primary tumor; and [c] no disease progression. GR pts were randomized (1:1) after surgery to four cycles MAP +/-Ifn. Ifn (0.5-1.0 μg/kg/wk) was given after CT until 2yr post registration. Primary endpoint: event free survival (EFS); secondary: overall survival, toxicity. The trial design sought improved 3yr EFS from 70% to 80% (80% power, 2-sided alpha 5%). The final analysis was planned after 147 EFS events. Results: 2,260 pts were registered (Apr 05 to Jun 11) from 17 countries (326 sites) making it the largest trial in this rare cancer. GR was reported in 1,034 pts and 715 consented to randomization (358 MAP, 357 MAPIfn) with baseline characteristics balanced by arm: median age 14yr, 59% male, 79% localized disease. 271/357 (76%) pts started Ifn; main reason for not starting was treatment refusal, 66/86. By Feb 13 234/271 had stopped Ifn. Median duration of Ifn if started was 455 days; grade 3+ toxicity during Ifn reported by 81pts (30%). Median follow-up is 3.1yr with 174 EFS events reported: 93 MAP, 81 MAPIfn. Hazard ratio for EFS from adjusted Cox model was 0.82 (95% CI 0.61-1.11; p=0.201) in favor of MAPIfn. Conclusions: With current follow-up, EFS for MAPIfn is not statistically superior to MAP alone in pts with high-grade osteosarcoma and good response to pre-op MAP. One-quarter of pts did not start Ifn, which may have influenced this finding. Further follow-up for events and survival continues. Clinical trial information: NCT00134030.
Genomic sequencing in pandemics
Authors: None The Lancet
Journal: The Lancet (2021)

Advanced genetic sequencing techniques have undoubtedly provided valuable information on the biology and evolution of SARS-CoV-2. Never have the nearly 30 000 nucleotides of a virus been so closely considered by scientists, public health experts, and politicians alike. But the use and application of genetic surveillance of SARS-CoV-2 has varied, risking an insufficient response to a rapidly changing pandemic.
Going viral: misinformation in the time of COVID-19
Authors: None The Lancet Rheumatology
Journal: The Lancet Rheumatology (2021)

False information and fake news have become increasingly prevalent during the COVID-19 pandemic, spreading rapidly through social media and other outlets, creating confusion and distrust. For patients managing chronic conditions, such as rheumatic and musculoskeletal diseases, finding accurate health information during the pandemic has serious implications for their health and quality of life.
February 23–March 1, 2013
Journal: The Lancet (2013)

Sugar solution?Public health offi cials are urging the US Food and Drug Administration (FDA) to set a safe limit on the amount of sugars in soft drinks.The FDA pledged in 1982 and 1988 to reassess the safety of "caloric sweeteners" if they became a public health hazard.Soft drinks are now the biggest source of sugars in the American diet.
News in brief
Authors: Jane Bradbury
Journal: The Lancet Infectious Diseases (2013)

HIV infection is often associated with infection with other sexually transmitted pathogens, particularly herpes simplex virus 2 (HSV-2). HSV-2 infections increase the risk of HIV acquisition and can worsen the clinical course of HIV disease. Thus, a microbicide that is active against both viruses would be very useful. Researchers now report that PMEO-DAPym, which is structurally related to tenofovir and adefovir, efficiently inhibits HIV-1 reverse transcriptase and HSV-2 DNA polymerase. In addition, PMEO-DAPym induces the production of CC-chemokines and downregulates the HIV-1 co-receptor CCR5, and could, therefore, prevent the entry of HIV into its host cells.
Medullary carcinoma of the colon: A comprehensive analysis of a large cancer database.
Authors: Iktej Singh Jabbal, Arun Nagarajan, Carlos Rivera, Marita Yaghi, Hong Liang, Zeina A. Nahleh, Pablo Bejarano, Mariana Berho, Steven Wexner
Journal: Journal of Clinical Oncology (2022)

180 Background: Medullary carcinoma (MC) of the colon was described first in 1999 and is characterized by undifferentiated sheets of epithelial cells in a solid growth pattern with pushing borders and prominent lymphoplasmacytic infiltrates. It frequently shows microsatellite instability (MSI). However, the clinicopathological and survival outcomes between MC and the more common adenocarcinoma of the colon (AC) are not well defined in a large database. Therefore, we used a large national registry to explore the association of survival characteristics with sociodemographic, geographic, and disease variables in this cohort of patients. Methods: We sampled the National Cancer Database (NCDB) for colon cancer patients diagnosed with MC from 2004-2018. Multivariate cox regression models were used to compare hazard ratios for demographic, geographic, and disease characteristics. In addition, Kaplan-Meier survival plots were utilized to assess survival rate differences between MC and AC tumors located in the ascending, transverse, or descending colon. A p-value&lt;0.05 was considered statistically significant. Results: Only 2,709 (0.29%) of the 922,667 patients with AC had MC. MC was seen in older patients than AC (76 vs. 69 years). MC was also more common in females than AC (72.5 vs. 49%). The most striking finding in our analysis was the predominance of poorly differentiated (63%) and undifferentiated (21.7%) pathologies in MC. This was in sharp contrast to AC, where 15.8% of patients were poorly differentiated, and only 2% were undifferentiated. Furthermore, undifferentiated and poorly differentiated MC tumors had a poor prognosis (HR 1.45, 95% CI 1.26-1.68, p&lt;0.001 and HR 1.44, 95% CI 1.29-1.62, p&lt;0.001 respectively) as compared to the other histological grades. Another notable finding in our analysis was the high prevalence of MSI in MC vs. AC (82.4% vs. 25.9%). Cecal MC (HR 1) had the worst prognosis of any colonic site. Left-sided MC tumors also had an inferior prognosis compared to AC (63.21 vs. 87.72 months), although not statistically significant (p=0.217). Conclusions: Colon cancer presenting as undifferentiated or poorly differentiated with associated MSI should raise the possibility of a medullary carcinoma diagnosis. However, given the rarity and difficulty in its pathological delineation, MC may remain underdiagnosed. In the modern treatment era, with the approval of immunotherapy for metastatic MSI colon cancer patients, survival and outcomes for metastatic MC may be improved.